Outcome of unrelated transplants in patients with multiple myeloma

Bone Marrow Transplantation

Volumn 35, Issue 7, 2005, Pages 675-681

  Ballen, K K ^a   King, R ^b   Carston, M ^b   Kollman, C ^b   Nelson, G ^b   Lim, S ^c   Reece, D ^d   Giralt, S ^e   Vesole, D H ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NATIONAL MARROW DONOR PROGRAM   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Multiple myeloma; Unrelated donor

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; DISEASE SEVERITY; DONOR; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 17144389411     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704868     Document Type: Article

References (48)

1. Weber D, Dimopoulos M, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
2. Alexanian R, Dimopoulos M, Delasalle K et al. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887-890.
3. Blade J, San Miguel JF, Fontanillas M et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol 1996; 14: 2167-2173.
4. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10 334-342.
5. Myeloma Trialists Collaborative Group. Combination chemotherapy versus melphalan and prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842.
6. Osterborg A, Ahre A, Bjorkholm M et al. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients Stage III - a randomized study from MGCS. Eur J Hematol 1989; 43: 54-62.
7. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
8. Child JA, Morgan GJ, Davies Fe et al. High dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
9. Lennoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Blood 2000; 95: 7-11.
10. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
11. Vesole DH, Tricot G, Jagannath S et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88: 838-847.
12. Fermand JP, Chevret S, Ravaud P et al. High-dose chemo-radiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a Phase II trial involving 63 patients. Blood 1998; 82: 2005-2009.
13. Fassas A, Barlogie B, Ward S et al. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Brit J Hematol 2003; 123: 484-489.
14. 2). Leukemia 2004; 18: 133-138.
15. Desikan R, Barlogie B, Sawyer J et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remission and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
16. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem cell transplant for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
17. Mehta J, Singhal S. Graft versus myeloma. Bone Marrow Transplant 1998; 11: 835-843.
18. Majolini I, Corradini P, Scime R et al. High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. Bone Marrow Transplant 2003; 31: 767-773.
19. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312-1322.
20. Alyea E, Weller E, Schlossman R et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrrow Transplant 2003; 32: 1145-1151.
21. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787-2793.
22. Lee CK, Badros A, Barlogie B et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003; 31: 73-80.
23. Giralt S, Aleman A, Anagnostopoulos A et al. Fludarabine/melphalan conditioning for allogenenic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30 367-373.
24. Anasetti C, Beatty PG, Storb R et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990; 29: 79-81.
25. National Marrow Donor Program Statistics 2002. www.marrow.org
26. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
28. Mantel M. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
29. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
30. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hematopoietic stem cell transplantation. Br J Hematol 1998; 102: 1115-1123.
31. Cox DR. Regression models and life tables. JR Stat Soc B 1972; 34: 187-200.
32. Drobyski WR, Pelz C, Kahler-Babbitt C et al. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia. Biol Blood Marrow Transplant 1998; 4: 3-12.
33. Bjorkstrand B, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
34. LeBlanc R, Montminy-Metivier S, Belanger R et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 2001; 28: 841-848.
35. Orsini E, Alyea EP, Chillemi A et al. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 375-376.
36. Perez-Simon JA, Martino R, Alegre A et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Hematol 2003; 121: 104-108.
37. Tricot G, Spencer T, Sawyer J et al. Predicting long-term (>5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Hematol 2002; 116 211-217.
38. Kulkarni S, Powles RL, Treleaven JG et al. Impact of previous high-dose therapy on outcomes after allografting for multiple myeloma. Bone Marrow Transplant 2000; 23: 675-680.
39. Kernan NA, Bartsch G, Ash RC. Analysis of 462 transplantations from unrelated donor facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
40. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
41. Slavin S, Nagler A, Naprstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
42. Khouri IS, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
43. Badros A, Barlogie B, Morris C et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295-1303.
44. Giralt S, Aleman A, Anagnostopoulos A et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30 367-373.
45. Kroger N, Sayer HG, Schwerdtfeger R et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-3924.
46. Shaw BE, Peggs K, Bird JM et al. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. Br J Hematol 2003; 123: 886-895.
47. Maloney DG, Molina AJ, Sahebi F et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102 3447-3454.
48. Kroger N, Schwerdtfeger R, Kiehl M et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-760.